Vir Biotechnology (VIR) Earnings Date & Reports

Key Takeaways

• Vir Biotechnology (NASDAQ: VIR) is expected to report third-quarter 2026 results on or around November 4, 2026, after the market close.
• Wall Street consensus calls for a loss of about $0.73 per share (EPS), a narrower loss than the $1.17 per share reported a year earlier.
• Revenue is expected to fall back to roughly $0.87 million, down sharply from $238.9 million in the prior quarter, which was inflated by a one-time collaboration payment from Astellas.
• Investors will focus on the company's cash position of about $1.01 billion, its runway into the second half of 2028, and spending on research and development (R&D).
• The biggest catalyst is not the income statement but the upcoming ECLIPSE-1 Phase 3 hepatitis delta (HDV) trial readout, expected in the fourth quarter of 2026.

Earnings Context and Why It Matters

Vir Biotechnology is a clinical-stage immunology company that has pivoted from its COVID-19 legacy toward treatments for hepatitis delta virus (HDV) and oncology. Its second-quarter 2026 results were unusually strong because of a $238.9 million license and collaboration payment tied to a global agreement with Astellas, which also included a $315 million upfront and equity investment. That one-time revenue turned the quarter profitable, but it is not recurring. The third-quarter report therefore offers investors a more normalized view of the company's underlying operating costs and cash burn, while setting the stage for pipeline milestones that could define its future.

Earnings Expectations

Analysts expect Vir Biotechnology to post a net loss of approximately $0.73 per share for the third quarter of 2026, with individual estimates ranging from a loss of $0.58 to $0.95 per share. That compares with a loss of $1.17 per share in the same period a year ago. The consensus revenue estimate sits at about $0.87 million, though forecasts vary widely, reflecting the unpredictable timing of collaboration and licensing payments rather than steady product sales.

These figures highlight the importance of looking beyond the headline numbers. The company has guided that its cash, cash equivalents, and investments — roughly $1.01 billion at the end of the second quarter — should fund operations into the second half of 2028. Key metrics to watch include R&D expense, selling, general and administrative (SG&A) costs, and any update to that cash-runway guidance. Last quarter, R&D expense reached $135.3 million, partly driven by milestone payments, so the pace of clinical investment will be closely scrutinized.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings catalysts across biotechnology and other sectors, the AI Screener offers a structured way to surface candidates worth a closer look.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautiously optimistic, driven more by the pipeline than by near-term financials. Vir Biotechnology shares traded around $11.50 to $11.70 in mid-October 2026, having risen meaningfully since the August 5 earnings release, when management highlighted strong Phase 2 SOLSTICE data showing an 88% "target not detected" (TND) rate — meaning the virus was undetectable — for its elebsiran plus tobevibart combination in hepatitis delta.

Still, key risk factors remain. The company has no recurring product revenue, depends heavily on collaboration economics, and faces binary clinical-trial outcomes. With consensus expecting a return to a loss, the market's reaction may hinge less on the per-share figure and more on management's commentary about ECLIPSE-1 timing, cash discipline, and progress in oncology.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the ECLIPSE-1 Phase 3 trial, with topline data expected in the fourth quarter of 2026. This registrational study could form the basis of a future filing in hepatitis delta, a serious and widely underdiagnosed liver disease. Additional readouts from the ECLIPSE-2 and ECLIPSE-3 studies are expected in the first quarter of 2027.

In oncology, investors will watch for updates on VIR-5500, a masked T-cell engager being developed with Astellas across several prostate cancer populations, with Phase 3 trials potentially starting next year. The company has also said it expects updated data from its VIR-5818 program in the second half of 2026.

On the operational side, Vir Biotechnology is preparing for potential commercialization of its hepatitis delta therapy, including work on at-home dosing and a planned European launch with partner Norgine. Leadership transitions are also underway, with searches for a new chief medical officer and chief financial officer. Together, these factors mean the earnings print is only one piece of a much larger story for investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations